Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sigrun Hallmeyer

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Current Treatment Options in Oncology|August 13, 2016
Sequencing of New and Old Therapies for Metastatic MelanomaMegan Ratterman, Sigrun Hallmeyer, Jon Richards
Cureus|February 6, 2016
High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced MelanomaMajid Mohiuddin, Harold Park, Sigrun Hallmeyer, et al.
AJP Reports|March 4, 2017
Management of Breast Cancer during Pregnancy: Are We Compliant with Current Guidelines?Victoria Shlensky, Sigrun Hallmeyer, Lourdes Juarez, et al.
Biology Methods & Protocols|March 6, 2023
Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosingSigrun Hallmeyer, Michael A Thompson, Veronica Fitzpatrick, et al.
Healthcare (Basel, Switzerland)|February 25, 2022
A Prospective, Longitudinal Evaluation of SARS-CoV-2 COVID-19 Exposure, Use of Protective Equipment and Social Distancing in a Group of Community PhysiciansEli D Ehrenpreis, Sigrun Hallmeyer, David H Kruchko, et al.
Journal of Patient-Centered Research and Reviews|August 8, 2022
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic MalignanciesMichael A Thompson, Sigrun Hallmeyer, Veronica E Fitzpatrick, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2005
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptideSupriya Perambakam, Sigrun Hallmeyer, Samarth Reddy, et al.
Cancer Medicine|April 28, 2016
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE studyMark R Middleton, Stéphane Dalle, Joel Claveau, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI studyBrendan D Curti, Jon Richards, John R Hyngstrom, et al.
Head & Neck|July 14, 2016
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanomaRobert H I Andtbacka, Sanjiv S Agarwala, David W Ollila, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Current Treatment Options in Oncology|August 13, 2016
Sequencing of New and Old Therapies for Metastatic MelanomaMegan Ratterman, Sigrun Hallmeyer, Jon Richards
Cureus|February 6, 2016
High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced MelanomaMajid Mohiuddin, Harold Park, Sigrun Hallmeyer, et al.
AJP Reports|March 4, 2017
Management of Breast Cancer during Pregnancy: Are We Compliant with Current Guidelines?Victoria Shlensky, Sigrun Hallmeyer, Lourdes Juarez, et al.
Biology Methods & Protocols|March 6, 2023
Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosingSigrun Hallmeyer, Michael A Thompson, Veronica Fitzpatrick, et al.
Healthcare (Basel, Switzerland)|February 25, 2022
A Prospective, Longitudinal Evaluation of SARS-CoV-2 COVID-19 Exposure, Use of Protective Equipment and Social Distancing in a Group of Community PhysiciansEli D Ehrenpreis, Sigrun Hallmeyer, David H Kruchko, et al.
Journal of Patient-Centered Research and Reviews|August 8, 2022
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic MalignanciesMichael A Thompson, Sigrun Hallmeyer, Veronica E Fitzpatrick, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2005
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptideSupriya Perambakam, Sigrun Hallmeyer, Samarth Reddy, et al.
Cancer Medicine|April 28, 2016
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE studyMark R Middleton, Stéphane Dalle, Joel Claveau, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI studyBrendan D Curti, Jon Richards, John R Hyngstrom, et al.
Head & Neck|July 14, 2016
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanomaRobert H I Andtbacka, Sanjiv S Agarwala, David W Ollila, et al.
Pageof 3